

**Advent Pharma Ltd.**  
**Statement of Financial Position(Un-audited)**  
**As at September 30, 2020**

Particulars	Notes	Amount in Taka	
		30-Sep-2020	30-Jun-2020
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>		<b>1,167,247,202</b>	<b>1,104,525,308</b>
Property, Plant and Equipment	4.00	1,089,290,539	1,098,601,145
Capital Work in Progress (Building Construction)	5.00	77,956,663	5,924,163
Right of use Assets		874,247	1,019,955
<b>CURRENT ASSETS</b>		<b>248,030,688</b>	<b>266,232,759</b>
Inventories	6.00	68,854,356	67,886,459
Trade and Other Receivable		108,520,145	118,236,156
Advances, Deposits and Pre-payments		27,825,344	33,771,482
Investment in FDR	7.00	40,000,000	40,000,000
Cash and Cash Equivalents	8.00	2,830,843	6,338,662
<b>Total Assets</b>		<b>1,416,152,137</b>	<b>1,371,778,022</b>
<b>SHAREHOLDERS' EQUITY AND LIABILITIES</b>			
<b>SHAREHOLDERS' EQUITY</b>		<b>1,154,219,290</b>	<b>1,120,590,279</b>
Share Capital	9.00	830,060,000	830,060,000
Retained Earnings	10.00	324,159,290	290,530,279
<b>NON-CURRENT LIABILITIES</b>		<b>123,945,700</b>	<b>118,436,964</b>
Long Term Borrowings - Net of Current Portion		16,516,175	16,516,175
Deferred Tax Liabilities	11.00	107,096,285	101,428,244
Liabilities for lease net current maturity	12.00	333,240	492,545
<b>CURRENT LIABILITIES</b>		<b>137,987,147</b>	<b>132,750,779</b>
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Payable to IPO Applicants		109,355	109,355
Short Term Borrowings		25,460,523	23,358,077
Trade and other payables		20,012,693	23,896,162
Liabilities for Lease-current maturity	12.00	667,160	649,231
Liabilities for expenses		4,407,980	6,110,913
Liability for contribution to WPPF		24,087,641	21,344,570
Provision for Current Tax	13.00	55,328,832	49,369,509
<b>Total Liabilities</b>		<b>261,932,846</b>	<b>251,187,743</b>
<b>Total Shareholders' Equity and Liabilities</b>		<b>1,416,152,137</b>	<b>1,371,778,022</b>
<b>Net Asset Value (NAV) per Share</b>	21.00	<b>13.91</b>	<b>13.50</b>

Company Secretary   Chief Financial Officer   Director   Managing Director   Chairman

Dated: November 14, 2020

Place: Dhaka

**Advent Pharma Ltd.**  
**Statement of Profit or Loss and Other Comprehensive Income(Un-audited)**  
**For the period from 01 July 2020 to September 30, 2020**

Particulars	Notes	Amount in Taka	
		July 01, 2020 to Sept 30, 2020	July 01, 2019 to Sept 30, 2019
<b>A Revenues</b>		129,526,361	172,464,278
<b>B Cost of Sales</b>	14.00	(73,088,190)	(89,560,083)
<b>C Gross Profit</b>		<b>56,438,171</b>	<b>82,904,195</b>
<b>Operating Expenses</b>		<b>(10,404,993)</b>	<b>(13,636,208)</b>
<b>D Administrative expenses</b>	16.00	(3,965,314)	(5,125,272)
Selling & Marketing Expenses	17.00	(6,439,679)	(8,510,936)
<b>E Operating Profit</b>		<b>46,033,178</b>	<b>69,267,987</b>
<b>Non Operating Expenses</b>		<b>(1,646,676)</b>	<b>(1,175,593)</b>
<b>F Financial Expenses</b>	18.00	(1,646,676)	(1,175,593)
<b>G Other Income</b>	19.00	3,132,692	6,203,437
<b>H Profit Before W.P.P.F</b>		<b>47,519,194</b>	<b>74,295,831</b>
<b>I Expenses for W.P.P.F</b>		<b>(2,262,819)</b>	<b>(3,537,897)</b>
<b>J Profit Before Tax</b>		<b>45,256,375</b>	<b>70,757,934</b>
<b>K Income Tax Expenses</b>		<b>(11,627,364)</b>	<b>(18,309,828)</b>
Current Tax	13.00	(5,959,323)	(14,145,208)
Deferred Tax	11.00	(5,668,041)	(4,164,620)
<b>L Net Profit After Tax</b>		<b>33,629,011</b>	<b>52,448,106</b>
<b>M Other Compresensive Income</b>		-	-
<b>N Total Comprehensive Income</b>		<b>33,629,011</b>	<b>52,448,106</b>
<b>O Adjusted Earnings per Share (EPS)</b>	20.00	<b>0.41</b>	<b>0.63</b>
<b>Basic Earnings per Share(EPS)</b>		<b>0.41</b>	<b>0.70</b>

Company Secretary   Chief Financial Officer   Director   Managing Director   Chairman

Dated: November 14, 2020  
Place: Dhaka

**Advent Pharma Ltd.**  
**Statement of Changes in Equity(Un-audited)**  
**For the Period ended September 30, 2020**

<b>Particulars</b>	<b>Ordinary Share Capital</b>	<b>Retained Earnings</b>	<b>Total</b>
<b>Balance as on July 01, 2020</b>	830,060,000	290,530,279	1,120,590,279
Net Profit for the period	-	33,629,011	33,629,011
<b>Balance as on Sept 30, 2020</b>	<b>830,060,000</b>	<b>324,159,290</b>	<b>1,154,219,290</b>

**Advent Pharma Ltd.**  
**Statement of Changes in Equity(Un-audited)**  
**For the period ended September 30, 2019**

<b>Particulars</b>	<b>Ordinary Share Capital</b>	<b>Retained Earnings</b>	<b>Total</b>
<b>Balance as on July 01, 2019</b>	<b>754,600,000</b>	<b>264,034,442</b>	<b>1,018,634,442</b>
Net Profit for the period	-	52,448,106	52,448,106
<b>Balance as on Sept 30, 2019</b>	<b>754,600,000</b>	<b>316,482,548</b>	<b>1,071,082,548</b>

**Company Secretary    Chief Financial Officer    Director    Managing Director    Chiarmman**

Dated: November 14, 2020  
Place: Dhaka

**Advent Pharma Ltd.**  
**Statement of Cash Flows(Un-audited)**  
**For the Period ended September 30, 2020**

Particulars	Amount in Taka	
	July 01, 2020 to Sept. 30, 2020	July 01, 2019 to Sept. 30, 2019
<b>A. CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Cash Receipts from Customers & Others	142,375,064	157,993,162
Cash Paid to Suppliers	(63,975,963)	(83,871,846)
Cash paid to Employees	(9,251,625)	(10,995,831)
Cash paid to Others	(5,797,666)	(8,358,879)
Tax Paid During This period	(375,838)	(1,804,455)
<b>Net cash generated from operating activities</b>	<b>62,973,972</b>	<b>52,962,151</b>
<b>B. CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Paid for Acquisition of Property, Plant & Equipment	(60,920)	(52,054,632)
Paid for Capital Work -in- Progress (construction)	(65,163,500)	(13,924,946)
Investment in FDR	-	30,000,000
<b>Net cash used for investing activities</b>	<b>(65,224,420)</b>	<b>(35,979,578)</b>
<b>C. CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Short Term Borrowings- Received/(Payment)	2,102,446	2,929,297
Long Term Borrowings-Received/(Payment)	-	(2,463,220)
Financial Expenses Paid	(1,045,936)	(1,343,628)
Cash Dividend Paid	(2,141,382)	(20,035)
Lease Payment	(172,500)	-
Refund to IPO Applicants	-	(10,000)
<b>Net cash provided by financing activities</b>	<b>(1,257,372)</b>	<b>(907,586)</b>
<b>D. Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>(3,507,819)</b>	<b>16,074,988</b>
<b>E. Cash &amp; Cash equivalents at the beginning of the period</b>	<b>6,338,662</b>	<b>8,742,883</b>
<b>F. Cash &amp; Cash equivalents at the end of the period (D+E)</b>	<b>2,830,843</b>	<b>24,817,871</b>
<b>G. Net Operating Cash Flows Per Share</b>	<b>22</b>	<b>0.76</b>
		<b>0.64</b>

Company Secretary    Chief Financial Officer    Director    Managing Director    Chiarmman

Dated: November 14, 2020  
Place: Dhaka

**Advent Pharma Limited**  
**Notes, comprising a summary of significant accounting policies and other explanatory information**  
**as at and for the period ended 30 Sept.-2020**

**1.00 Corporate History of the Reporting Entity**

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016.

**2.00 Corporate Business**

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

**3.00 Basis of preparation and significant accounting policies**

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities Exchange Rules 1987 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segment
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases

		Amount in Taka	
		30-Sep-2020	30-Jun-2020
<b>4.00 Property, Plant and Equipment</b>			
A. Cost			
Opening Balance		1,214,404,201	927,415,596
Add: Addition during the Period		60,920	286,988,605
Less: Disposal during the Period		-	-
		<b>1,214,465,121</b>	<b>1,214,404,201</b>
B. Accumulated Depreciation			
Opening Balance		115,803,056	82,685,733
Add: Depreciation charged during the Period		9,371,526	33,117,323
Less: Adjustment during the Period		-	-
		<b>125,174,582</b>	<b>115,803,056</b>
<b>Written down Value (A-B)</b>		<b>1,089,290,539</b>	<b>1,098,601,145</b>
<i>Details are shown in Annexure-A.</i>			
<b>5.00 Capital Work In Progress (Building Construction)</b>			
Opening Balance		5,924,163	86,451,054
Addition during the Period		72,032,500	150,778,461
Transfer to Factory Building		-	(231,305,352)
<b>Closing Balance</b>		<b>77,956,663</b>	<b>5,924,163</b>
<b>6.00 Inventories</b>			
Finished Goods (Note-14.00)		26,225,405	24,923,097
Raw Materials		22,520,203	22,320,203
Packing Materials		6,215,512	6,055,256
Spare Parts		90,785	185,452
Work In Process (Note-14.00)		13,802,451	14,402,451
<b>Total</b>		<b>68,854,356</b>	<b>67,886,459</b>
<b>7.00 Investment in FDR</b>			
<b><u>Name of Financial Institution</u></b>			
Midland Bank Ltd. FDR No.: 0019761		40,000,000	40,000,000
<b>Total</b>		<b>40,000,000</b>	<b>40,000,000</b>
<b>8.00 Cash &amp; Cash Equivalents</b>			
Cash in hand (Note-8.01)		41,628	135,502
Cash at bank (Note-8.02)		2,789,215	6,203,160
<b>Total</b>		<b>2,830,843</b>	<b>6,338,662</b>
<b>8.01 Cash in Hand</b>			
Head Office		40,511	65,587
Depots		1,117	69,915
		<b>41,628</b>	<b>135,502</b>
<b>8.02 Cash at Bank (Note- 8.02.01)</b>		<b>2,789,215</b>	<b>6,203,160</b>
<b>8.02.01 Cash at Bank</b>			
<b><u>Bank Name</u></b>			
Islami Bank Bangladesh Ltd. A/C No. # 283517		305,694	265,542
Dutch Bangla Bank Ltd. A/C No. # 129775		1,955,616	688,718
Janata Bank Ltd A/C No. # 10035785		37,596	197,721
IFIC Bank Ltd. A/C No. # 327-041		50,676	4,028,654
IFIC Bank Ltd. A/C No. # 327-001		43,178	43,178
IFIC Bank Ltd. A/C No. # 327-003		89,852	81,294
Shahjalal Islami Bank Ltd. A/C No. # 000-7339		22,810	22,810
Midland Bank Ltd. A/C No. # 000-6230		104,995	696,445
BRAC Bank Ltd. A/C No. # 150001		94,826	94,826
BRAC Bank Ltd. A/C No. # 150002		83,972	83,972
<b>Total</b>		<b>2,789,215</b>	<b>6,203,160</b>

		Amount in Taka	
		30-Sep-2020	30-Jun-2020
9.00	<b>Share Capital</b>		
	<b><u>Authorized Capital :</u></b>		
	100,000,000 ordinary shares of Tk. 10.00 each	<b>1,000,000,000</b>	<b>1,000,000,000</b>
	<b><u>Issued, Subscribed &amp; Paid-up Capital :</u></b>		
	754,60,000 ordinary shares of Tk. 10.00 each	<b>830,060,000</b>	<b>830,060,000</b>
	830,06,000 ordinary shares of Tk. 10.00 each		

Category of Shareholders	No. of Share Holding		Percentage of Shareholding		Amount in Taka	
	30-Sep-20	30-Jun-20	30-Sep-20	30-Jun-20	30-Sep-20	30-Jun-20
Director & Sponsor	26,096,675	26,096,675	31.44%	31.44%	260,966,750	260,966,750
Institutional	18,427,332	16,219,372	22.20%	19.54%	184,273,320	184,273,320
Public	38,481,993	40,689,953	46.36%	49.02%	384,819,930	384,819,930
<b>Total</b>	<b>83,006,000</b>	<b>83,006,000</b>	<b>100%</b>	<b>100%</b>	<b>830,060,000</b>	<b>830,060,000</b>

Balance brought forward	290,530,279	264,034,442
Add: Profit for the Period	33,629,011	117,054,459
Stock Dividend	-	(75,460,000)
Cash Dividend	-	(15,092,000)
Adjustment for Leased Assets	-	(6,622)
<b>Balance carried forward</b>	<b>324,159,290</b>	<b>290,530,279</b>

<b>Opening Balance</b>	101,428,244	66,999,086
Add: Provision made during the period (Note-11.01)	5,668,041	34,429,158
<b>Closing Balance</b>	<b>107,096,285</b>	<b>101,428,244</b>

Written Down Value of PPE as per Accounting Base	1,089,290,539	1,098,601,145
Written Down Value as per Third Schedule	(660,905,400)	(692,888,168)
<b>Net Temporary Difference</b>	<b>428,385,139</b>	<b>405,712,977</b>
Income Tax Rate	25%	25%
<b>Deferred Tax Liability</b>	<b>107,096,285</b>	<b>101,428,244</b>
Opening Deferred Tax Liability	(101,428,244)	(66,999,086)
<b>Deferred Tax Expenses</b>	<b>5,668,041</b>	<b>34,429,158</b>

<b>Beginning Balance</b>	1,141,776	1,609,407
<sup>2010</sup> <sup>Interest</sup>		
-----	31,124	164,869
Less: Payment	172,500	632,500
<b>Closing Balance</b>	<b>1,000,400</b>	<b>1,141,776</b>
Less: Liabilities for lease-current maturity	(667,160)	(649,231)
<b>Total</b>	<b>333,240</b>	<b>492,545</b>

Opening Balance	49,369,509	58,922,680
Add: Provision for tax during the period (Note-13.01)	5,959,323	10,025,596
Less: Paid during the period/Adjustment	-	(19,578,767)
<b>Total</b>	<b>55,328,832</b>	<b>49,369,509</b>

Accounting Profit before Tax	45,256,375	161,509,212
<b>Add: Other Inadmissible Allowances</b>		
Accounting Depreciation	9,371,526	33,117,323
Other Income	(3,132,692)	(10,817,225)
<b>Less: Items for Separate Consideration</b>		
Depreciation as per 3rd Schedule	(32,043,688)	(158,851,042)
<b>Total Taxable Income</b>	<b>19,451,521</b>	<b>24,958,268</b>
<b>Rate</b>	25%	25%
<b>Total Tax Expenses/Current Tax</b>	<b>4,862,880</b>	<b>6,239,567</b>
<b>Tax on other income</b>	<b>1,096,442</b>	<b>3,786,029</b>
<b>Total Tax Payable</b>	<b>5,959,323</b>	<b>10,025,596</b>

	July 01, 2020 to Sept 30, 2020	July 01, 2019 to Sept. 30, 2019
<b>14.00 Cost of Sales</b>		
Raw Materials Consumed	58,817,479	78,402,418
Manufacturing Overhead (Note-15.00)	15,261,236	16,351,268
	<b>74,078,715</b>	<b>94,753,686</b>
Add: Opening Work in process	14,402,451	13,546,890
Less: Closing Work in process	(13,802,451)	(10,803,245)
<b>Cost of Goods Manufactured</b>	<b>74,678,715</b>	<b>97,497,331</b>
Add: Opening stock of finished Goods	24,923,097	22,786,458
<b>Cost of Goods Available for Sale</b>	<b>99,601,812</b>	<b>120,283,789</b>
Less: Closing stock of finished Goods	(26,225,405)	(30,384,853)
Less: Sample Distribution	(288,217)	(338,853)
<b>Cost of Sales</b>	<b>73,088,190</b>	<b>89,560,083</b>
<b>15.00 Manufacturing Overhead</b>		
Wages and Salary	2,474,746	2,899,736
Festival Bonus	238,388	526,777
Overtime	-	496,755
Packaging Materials Consumed	2,199,251	2,379,807
Spare Parts Consumed	204,680	516,501
Repair & Maintenance	163,561	311,795
Electricity Bill (Factory)	456,514	499,043
Disel & Fuel	44,200	362,400
Electric & Sanitary Goods	16,271	311,915
Fire Insurance Premium	43,523	25,260
Canteen Expenses	350,448	551,498
Laboratory Expenses	14,250	1,000
Cleaning & Washing	15,821	17,460
Internet bill	12,000	7,900
Mobile & Telephone bill	8,000	4,900
Uniform	49,790	33,045
Depreciation (Annexure-A)	8,969,793	7,405,476
<b>Total</b>	<b>15,261,236</b>	<b>16,351,268</b>
<b>16.00 Administrative Expenses</b>		
Salary & Allowance	2,063,250	2,805,661
Director Remuneration (Note # 24.00)	300,000	300,000
Conveyance	25,035	48,479
Subscription, Gift & Donation	17,700	4,300
Festival Bonus	148,375	319,550
Office Rent including VAT	-	172,500
Board meeting attendance fees (Note # 24.00)	45,000	45,000
Cleaning & Sanitation	12,098	5,586
Electricity Bill	73,599	57,752
Entertainment	64,678	68,092
Garage Rent	5,400	6,400
Legal, License & Renewal & Professional fee	112,305	180,463
Reaserch & Product Development	4,500	4,095
Miscellaneous Expense	162,440	156,306
Newspaper & Magazine	-	2,100
Postage, Stamps & Courier	5,595	9,535
Printing & Stationery	44,616	132,310



	July 01, 2020 to Sept 30, 2020	July 01, 2019 to Sept. 30, 2019
Office Maintenance	47,535	50,495
Traning Allowance	-	12,000
Vehicle Repair & Maintenance	21,315	22,222
Fuel & Gas	55,676	140,582
Telephone & Mobile	64,382	92,795
Internet bill	27,000	28,000
Audit Fees Includind VAT	86,250	57,500
Interest expenses on the Lease Liability	31,124	-
Depreciation Charge for the Right-of-Use Asset	145,708	-
Depreciation (Annexure-A)	401,733	403,549
<b>Total</b>	<b>3,965,314</b>	<b>5,125,272</b>

**17.00 Selling & Marketing Expenses**

Salary & Allowance	3,326,133	3,249,610
Travelling & Conveyance	744,900	1,258,093
Festival Bonus	224,158	466,935
Advertisement	22,800	3,098
Marketing Promotion	207,964	1,070,847
Distribution Cost	1,625,507	2,123,500
Sample Distribution	288,217	338,853
<b>Total</b>	<b>6,439,679</b>	<b>8,510,936</b>

**18.00 Financial Expenses**

Bank Charges	15,777	77,091
Interest on Loan	1,150,646	1,098,502
Interest on W.P.P.F Fund used	480,253	-
<b>Total</b>	<b>1,646,676</b>	<b>1,175,593</b>

**19.00 Other Income**

Interest on FDR	1,700,000	6,100,000
Sales of Wastage(Others)	65,647	103,437
Toll Manufacturing Income	1,367,045	-
<b>Total</b>	<b>3,132,692</b>	<b>6,203,437</b>

**20.00 Basic Earnings Per Share**

Profit after tax	
Weighted average number of ordinary shares outstanding	Note-20.01
<b>Basic Earnings per Share</b>	

Quarterly Product	
30-Sep-2020	30-Sep-2019
33,629,011	52,448,106
83,006,000	75,460,000
<b>0.41</b>	<b>0.70</b>

**Adjusted Earnings per Share:**

Profit after tax	
Weighted average number of ordinary shares outstanding	Note-20.01
<b>Basic Earnings per Share(Adjusted )</b>	

33,629,011	52,448,106
83,006,000	83,006,000
<b>0.41</b>	<b>0.63</b>

**Diluted Earnings per Share:**

Profit after tax	
Weighted average number of ordinary shares outstanding	Note-20.01
<b>Diluted Earnings per Share</b>	

33,629,011	52,448,106
83,006,000	83,006,000
<b>0.41</b>	<b>0.63</b>

As there are no shares under option, Basic & Diluted earnings per share are same for the period. This has been calculated in compliance with the requirements of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the period.

**20.01 Calculation of Weighted Average Number of Shares**

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Quarterly Product (Weighted Average)	
					30-Sep-2020	30-Sep-2019
Shares at beginning	75,460,000	July-20 to Sept-20	92	6,942,320,000	75,460,000	75,460,000
Stock Dividend -2019@ 10%	7,546,000	July-20 to Sept-20	92	694,232,000	7,546,000	7,546,000
<b>Total</b>	<b>83,006,000</b>			<b>7,636,552,000</b>	<b>83,006,000</b>	<b>83,006,000</b>

**21.00 Net Asset Value (NAV) per Share**

Total Asset
Less: Total outside Liability
<b>Net Asset</b>
Number of ordinary shares outstanding
<b>Net Assets Value (NAV) per Share</b>

30-Sep-2020	30-Jun-2020
1,416,152,137	1,371,778,022
261,932,846	251,187,743
<b>1,154,219,290</b>	<b>1,120,590,279</b>
83,006,000	83,006,000
<b>13.91</b>	<b>13.50</b>

**22.00 Net Operating Cash Flows per Share(NOCFPS)**

Net Cash Generated From Operating Activities
Weighted Average Number of Shares Outstanding
<b>Net Operating Cash Flows per Share(NOCFPS) (Adjusted)</b>

30-Sep-2020	30-Sep-2019
62,973,972	52,962,151
83,006,000	83,006,000
<b>0.76</b>	<b>0.64</b>

**23.00 Reconciliation of Net Profit with Cash flows from Operating Activities:**

<b>Profit before Tax</b>	<b>45,256,375</b>	<b>70,757,934</b>
Adjustment for:		
Depreciation on property, plant and equipment	9,371,526	7,809,025
Adjustment for depreciation of the Right Use of Assets	145,708	-
Interest expenses on Lease	31,124	-
Financial Expenses	1,646,676	1,175,593
	<b>56,451,409</b>	<b>79,742,552</b>
(Increase)/Decrease in Accounts Receivable	9,716,011	(20,674,553)
(Increase)/Decrease in Inventory	(967,897)	(7,653,177)
Increase/(Decrease) in Trade and Other Payables	(1,742,088)	455,088
Decrease/(Increase) in Advance, Deposit & Prepayments	(547,024)	(544,690)
Increase/(Decrease) in Liabilities for Expenses	(1,823,420)	(96,511)
(Increase)/Decrease in Liability for contribution to W.P.P.F	2,262,819	3,537,897
	<b>63,349,810</b>	<b>54,766,606</b>
Less: Income Tax Paid	(375,838)	(1,804,455)
<b>Net Cash Generated from Operating Activities</b>	<b>62,973,972</b>	<b>52,962,151</b>

30-Sep-2020	30-Sep-2019
45,256,375	70,757,934
9,371,526	7,809,025
145,708	-
31,124	-
1,646,676	1,175,593
56,451,409	79,742,552
9,716,011	(20,674,553)
(967,897)	(7,653,177)
(1,742,088)	455,088
(547,024)	(544,690)
(1,823,420)	(96,511)
2,262,819	3,537,897
63,349,810	54,766,606
(375,838)	(1,804,455)
62,973,972	52,962,151

**24.00 Related parties Transaction:**

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

**24.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation.****a) Short-term employee benefits :**

The amount of transaction for remuneration and board meeting fee during the period from 1st July 2020 to 30 th Sept 2020 are as follows:

Name	Designation	Remuneration	Board meeting fee
A.K.M. Shafiqul Alam	Chairman		5,000
Faria Binta Alam	Managing Director	300,000	5,000
Wajhi Ahmed	Director	-	5,000
Kazi Rina Alam	Director	-	5,000
Md. Tazul Islam	Director	-	5,000
Mohammad Towhidul Islam	Nominee Director	-	5,000
Asif Iqbal Chowdhury	Nominee Director	-	5,000
Mohammed Salim	Independent Director	-	5,000
Shekh Karimuzzaman	Independent Director	-	5,000
<b>Total</b>		<b>300,000</b>	<b>45,000</b>

**b) Post employment benefits: Nil****c) Other long term benefits: Nil****d) Termination benefits: Nil****e) Share-based payment: Nil****25.00 Significant Deviation**

Advent Pharma Ltd. Is veterinary medicine producer. Due to COVID-19 pandemic and flood and also seasonal variations our sales has decreased and materials price has increased in the market for interruption of Import. On the other hand carrying cost also has increased. All of this reason net profit after tax and earning per share has decreased and net operating cash flow per share has increased due to decrease of Accounts receivable proportionately from the previous period.

**Advent Pharma Ltd.**  
**Schedule of Property, Plant and Equipment**  
**As at September 30, 2020**

**Annexure-A**  
(Amount in Taka)

Particulars	Cost				Depreciation					Written down value as on 30-Sept-2020
	Balance as on 01-July-2020	Addition during the Period	Disposal during the Period	Balance as on 30-Sept-2020	Rate of Dep.	Balance as on 01-July-2020	Charged during the Period	Adjustment during the Period	Balance as on 30-Sept-2020	
Land	3,783,816	-	-	3,783,816	0%	-	-	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	2.5%	801,048	54,084	-	855,132	8,599,398
Factory Building	758,842,294	-	-	758,842,294	2.5%	34,439,549	4,527,517	-	38,967,066	719,875,228
Plant & Machinery	273,035,384	-	-	273,035,384	5%	43,794,758	2,865,508	-	46,660,266	226,375,118
Sub-Station	6,694,722	-	-	6,694,722	10%	2,706,287	99,711	-	2,805,998	3,888,724
Motor Vehicle	6,097,576	-	-	6,097,576	15%	3,195,020	108,846	-	3,303,866	2,793,710
Furniture & Fixture	8,059,885	50,920	-	8,110,805	10%	2,439,835	140,926	-	2,580,761	5,530,044
Solar Panel	2,004,740	-	-	2,004,740	10%	761,090	31,091	-	792,181	1,212,559
Generator	627,520	-	-	627,520	10%	337,106	7,260	-	344,366	283,154
Air Conditioner	4,254,120	-	-	4,254,120	5%	884,799	42,117	-	926,916	3,327,204
Office Equipment	6,431,313	5,200	-	6,436,513	10%	2,041,010	109,844	-	2,150,854	4,285,659
HVAC System	44,536,240	-	-	44,536,240	5%	8,102,093	455,427	-	8,557,520	35,978,720
Laboratory Equipment	51,322,810	4,800	-	51,327,610	5%	9,270,247	525,677	-	9,795,924	41,531,686
Product Development Equipment	20,725,781	-	-	20,725,781	5%	3,714,067	212,646	-	3,926,713	16,799,068
ETP	18,488,470	-	-	18,488,470	5%	3,297,400	189,888	-	3,487,288	15,001,182
Books & Journals	45,000	-	-	45,000	15%	18,747	984	-	19,731	25,269
<b>Total</b>	<b>1,214,404,201</b>	<b>60,920</b>	<b>-</b>	<b>1,214,465,121</b>		<b>115,803,056</b>	<b>9,371,526</b>	<b>-</b>	<b>125,174,582</b>	<b>1,089,290,539</b>
<b>Balance as at June 30, 2020</b>	<b>927,415,596</b>	<b>286,988,605</b>	<b>-</b>	<b>1,214,404,201</b>		<b>82,685,733</b>	<b>33,117,323</b>	<b>-</b>	<b>115,803,056</b>	<b>1,098,601,145</b>

**Allocation of Depreciation:**

Administrative cost	401,733
Factory cost	8,969,793
<b>Total</b>	<b>9,371,526</b>